Amendment to Schedule 13D Filing for Viskase Holdings, Inc.

This filing is an amendment to the Schedule 13D for Viskase Holdings, Inc. (formerly Enzon Pharmaceuticals, Inc.). On March 25, 2026, the reporting persons exchanged preferred stock for 5,658,396 shares of the Issuer's common stock. On March 26, 2026, the merger between the Issuer and Viskase Companies, Inc. was completed. In connection with the merger, the reporting persons received 7,407,489 shares of the Issuer in exchange for 150,810,078 shares of Viskase. Robert Flint, Colin Kwak, and Dustin DeMaria were appointed to the Issuer's board of directors. Carl Icahn, through his associated entities, now holds 93.7% of the outstanding shares, amounting to 13,426,451 shares, as of March 26, 2026.